Clinical Trials Logo

Clinical Trial Summary

This is a pilot, randomized, single-center, parallel group, open-label controlled study to evaluate the feasibility, safety, efficacy, and pharmacokinetics of nebulized HCQ01 plus Standard of Care (SOC) versus SOC alone in hospitalized cancer patients with COVID-19. King Hussein Cancer Center (KHCC) is the study sponsor, and the study will be conducted at KHCC COVID-19 wards. Approximately 28 cancer patients, ≥18 years of age with a confirmed SARS-CoV-2 infection, will be enrolled and randomized 1:1 to the treatment and control arms where they will receive ten doses of Hydroxychloroquine solution via nebulizer in addition to SOC or the control arm where treatment will follow KHCC SOC.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04731051
Study type Interventional
Source King Hussein Cancer Center
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date October 2022
Completion date December 2022

See also
  Status Clinical Trial Phase
Suspended NCT04334967 - Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Phase 4
Recruiting NCT05113810 - The Potential Use of Nebulized Hydroxychloroquine for the Treatment of COVID-19 Phase 2
Not yet recruiting NCT04246242 - A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV) Phase 4